Daewoong Completed Enrollment for Pulmonary Fibrosis Trial
The pharmaceutical firm finished recruiting 104 patients for a global Phase 2 study of the treatment candidate Bersiporocin.
Updated on Sept. 21, 2026 in Diseases — General
Live Poll
Should government agencies grant special status and market exclusivity to pharmaceutical firms for rare disease drugs?
Daewoong Pharmaceutical has successfully completed the enrollment process for its Phase 2 clinical trial investigating Bersiporocin for idiopathic pulmonary fibrosis. The study evaluates the treatment in 104 participants across the United States and South Korea.
Why it matters
Idiopathic pulmonary fibrosis is a condition characterized by abnormal collagen accumulation that causes lung tissue to harden and lose function. Developing new therapies for this disease is a primary focus for improving long-term respiratory outcomes.
The global Phase 2 study includes 55 participants in South Korea and 49 in the United States. Patients are receiving either Bersiporocin or a placebo twice daily over a 24-week treatment duration.
The players
Daewoong Pharmaceutical
This is a South Korean pharmaceutical company focused on developing innovative drugs for various therapeutic areas.
FDA
The U.S. Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices.
EMA
The European Medicines Agency is a scientific body responsible for the evaluation and supervision of pharmaceutical products in the European Union.
The details
Bersiporocin works by reducing the activity of proteins that drive collagen production in the lungs. Daewoong Pharmaceutical announced the enrollment milestone at the European Respiratory Society conference in Barcelona.
Timeline
September 21, 2026: Enrollment completion was announced at the ERS conference.
24 weeks: The duration for which patients receive treatment during the trial.
2027: The period when key clinical trial indicators are planned for announcement.
Health Landscape
This clinical trial reflects the broader industry move toward utilizing rare disease designations to accelerate development timelines. It follows a pattern set by the Orphan Drug Act, which provides incentives such as market exclusivity to encourage treatments for conditions like idiopathic pulmonary fibrosis.
The trial progress provides hope for future treatment options for patients currently managing lung-hardening conditions. If successful, Bersiporocin may reach the market with potential exclusivity protections of up to 7 years in the U.S. and 10 years in Europe.
The takeaway
This milestone represents a critical step in the rigorous testing required to bring new respiratory medications to the global market. Participants and providers should anticipate further efficacy data regarding the drug's impact on collagen production following the 24-week study window.
What happens next
Daewoong Pharmaceutical plans to release key indicators from the clinical trial in 2027.
Further reading
Learn more about the latest research in this field in the Diseases — General section.
Live Poll
Should government agencies grant special status and market exclusivity to pharmaceutical firms for rare disease drugs?
